MASLD: an emerging factor in the pathophysiology and clinical management of ICC

Abstract

This article explores the emerging role of metabolic dysfunction-associated steatotic liver disease (MASLD) in the pathophysiology of intrahepatic cholangiocarcinoma (ICC). Despite advances in public health, ICC incidence has risen, suggesting overlooked risk factors. Recent studies indicate a significant association between MASLD and ICC, though causality remains unproven. The article reviews current research, highlighting limitations such as retrospective designs and small sample sizes. It emphasizes the need for comprehensive investigations into MASLD’s role in ICC pathogenesis, prognosis, and management. Future research should focus on integrating advanced methodologies to identify novel biomarkers and therapeutic strategies, aiming to improve patient outcomes and develop tailored prevention and treatment approaches.

Keywords

Metabolic dysfunction-associated steatotic liver disease / intrahepatic cholangiocarcinoma / risk factors / pathogenesis / progression / prognosis / treatment

References

[1] Welzel TM,El-Serag HB.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.Clin Gastroenterol Hepatol2007;5:1221-8 PMCID:PMC2083573

[2] Kinoshita M,Tanaka S.The association between non-alcoholic steatohepatitis and intrahepatic cholangiocarcinoma: a hospital based case-control study.J Surg Oncol2016;113:779-83

[3] Wongjarupong N,Susantitaphong P.Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis.BMC Gastroenterol2017;17:149 PMCID:PMC5721586

[4] Petrick JL,Altekruse SF.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based study in SEER-Medicare.PLoS One2017;12:e0186643 PMCID:PMC5648218

[5] Zhou HB,Wang H.Risk factors of intrahepatic cholangiocarcinoma: a case-control study.Zhonghua Gan Zang Bing Za Zhi2009;17:935-9.

[6] Reddy SK,Marsh JW et al.Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma.J Gastrointest Surg2013;17:748-55 PMCID:PMC4007003

[7] Nkontchou G,Ziol M.Peripheral intrahepatic cholangiocarcinoma occurring in patients without cirrhosis or chronic bile duct diseases: epidemiology and histopathology of distant nontumoral liver in 57 White patients.Eur J Gastroenterol Hepatol2013;25:94-8

[8] Chang JS,Chen LT.Medical risk factors associated with cholangiocarcinoma in Taiwan: a population-based case-control study.PLoS One2013;8:e69981 PMCID:PMC3718690

[9] Choi J,Peeraphatdit T.Aspirin use and the risk of cholangiocarcinoma.Hepatology2016;64:785-96 PMCID:PMC5995727

[10] Xiong J,Xu W.Metabolic syndrome and the risk of cholangiocarcinoma: a hospital-based case-control study in China.Cancer Manag Res2018;10:3849-55 PMCID:PMC6161710

[11] Sirica AE,Groopman JD.Intrahepatic cholangiocarcinoma: continuing challenges and translational advances.Hepatology2019;69:1803-15 PMCID:PMC6433548

[12] De Lorenzo S,Mazzotta A.Non-alcoholic steatohepatitis as a risk factor for intrahepatic cholangiocarcinoma and its prognostic role.Cancers (Basel)2020;12:3182 PMCID:PMC7692633

[13] Corrao S,Argano C.Nonalcoholic fatty liver disease is associated with intrahepatic cholangiocarcinoma and not with extrahepatic form: definitive evidence from meta-analysis and trial sequential analysis.Eur J Gastroenterol Hepatol2021;33:62-8

[14] Ghidini M,Facciorusso A.Metabolic disorders and the risk of cholangiocarcinoma.Expert Rev Gastroenterol Hepatol2021;15:999-1007

[15] Eslam M,Sarin SK.A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.J Hepatol2020;73:202-9

[16] Crane H,Sharma A.MAFLD: an optimal framework for understanding liver cancer phenotypes.J Gastroenterol2023;58:947-64 PMCID:PMC10522746

[17] Golabi P,AlQahtani S,Tuncer G.Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: data from Global Burden of Disease 2009-2019.J Hepatol2021;75:795-809

[18] Hu S,Tao J.Therapeutic implication of SOX9 and YAP1 co-repression in advanced intrahepatic cholangiocarcinoma.The FASEB Journal2022;36

[19] Cadamuro M,Camerotto R.Intrahepatic cholangiocarcinoma developing in patients with metabolic syndrome is characterized by osteopontin overexpression in the tumor stroma.Int J Mol Sci2023;24:4748 PMCID:PMC10003180

[20] Ko S,Tao J.Simultaneous Yap and Sox9 repression eliminates Notch-dependent hepatocyte-driven cholangiocarcinogenesis.The FASEB Journal2020;34:1-1

[21] Cadamuro M,Brivio S.The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma.Biochim Biophys Acta Mol Basis Dis2018;1864:1435-43 PMCID:PMC6386155

[22] Sirica AE,Cadamuro M.Intrahepatic cholangiocarcinoma: morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.Adv Cancer Res2021;149:321-87 PMCID:PMC8800451

[23] Fabris L,Cagnin S,Gores GJ.Liver matrix in benign and malignant biliary tract disease.Semin Liver Dis2020;40:282-97

[24] Fava G,Rychlicki C.Leptin enhances cholangiocarcinoma cell growth.Cancer Res2008;68:6752-61 PMCID:PMC2556377

[25] Alzahrani B,Hebbard LW.Non-viral causes of liver cancer: does obesity led inflammation play a role?.Cancer Lett2014;345:223-9

[26] Lewitt MS,Hall K.The insulin-like growth factor system in obesity, insulin resistance and type 2 diabetes mellitus.J Clin Med2014;3:1561-74 PMCID:PMC4470198

[27] Gallagher EJ.Minireview: IGF, insulin, and cancer.Endocrinology2011;152:2546-51

[28] Weroha SJ.The insulin-like growth factor system in cancer.Endocrinol Metab Clin North Am2012;41:335-50 PMCID:PMC3614012

[29] Pollak M.The insulin and insulin-like growth factor receptor family in neoplasia: an update.Nat Rev Cancer2012;12:159-69

[30] Marzioni M,Alvaro D,Benedetti A.Control of cholangiocyte adaptive responses by visceral hormones and neuropeptides.Clin Rev Allergy Immunol2009;36:13-22 PMCID:PMC2628969

[31] Alvaro D,Franchitto A.Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma.Am J Pathol2006;169:877-88 PMCID:PMC1698823

[32] Shimizu Y,Gollin SM.Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells.Int J Cancer1992;52:252-60

[33] Xu L,Dietmaier W.Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.BMC Cancer2010;10:302 PMCID:PMC2896958

[34] Phoomak C,Silsirivanit A.High glucose levels boost the aggressiveness of highly metastatic cholangiocarcinoma cells via O-GlcNAcylation.Sci Rep2017;7:43842 PMCID:PMC5338328

[35] Saengboonmee C,Pairojkul C.High glucose enhances progression of cholangiocarcinoma cells via STAT3 activation.Sci Rep2016;6:18995 PMCID:PMC4705543

[36] Hebbard LW,Young LJ,Oshima RG.T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model.Cancer Res2008;68:1407-16 PMCID:PMC2676344

[37] Wendel HG,Fridman JS.Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy.Nature2004;428:332-7

[38] Clements O,Kim JU,Khan SA.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis.J Hepatol2020;72:95-103

[39] Chang L.Mammalian MAP kinase signalling cascades.Nature2001;410:37-40

[40] Yamauchi T,Ito Y.Cloning of adiponectin receptors that mediate antidiabetic metabolic effects.Nature2003;423:762-9

[41] Sirica AE.Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.World J Gastroenterol2008;14:7033-58 PMCID:PMC2776834

[42] Wang L,Zhao Y.Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience.J Transl Med2020;18:273 PMCID:PMC7336472

[43] Miyata T,Yoshizumi T.CXCL12 expression in intrahepatic cholangiocarcinoma is associated with metastasis and poor prognosis.Cancer Sci2019;110:3197-203 PMCID:PMC6778649

[44] Cen W,Tong C.Intrahepatic cholangiocarcinoma cells promote epithelial-mesenchymal transition of hepatocellular carcinoma cells by secreting LAMC2.J Cancer2021;12:3448-57 PMCID:PMC8120174

[45] Shi T,Kobara H.The role of microRNAs in cholangiocarcinoma.Int J Mol Sci2021;22:7627 PMCID:PMC8306241

[46] Pu T,Chen Z. Advances in molecular pathogenesis and treatment of intrahepatic cholangiocarcinoma. Available from: https://pesquisa.bvsalud.org/portal/resource/pt/wpr-865095 [Last accessed on 25 Sep 2024]

[47] Chen C.Advances in research, diagnosis and treatment of intrahepatic cholangiocarcinoma based on molecular mechanisms.Journal of Abdominal Surgery2022;35:245-51.

[48] Kisseleva T.Molecular and cellular mechanisms of liver fibrosis and its regression.Nat Rev Gastroenterol Hepatol2021;18:151-66

[49] Alison MR.Liver cancer: the role of stem cells.Cell Prolif2005;38:407-21 PMCID:PMC6496116

[50] Roskams T.Liver stem cells and their implication in hepatocellular and cholangiocarcinoma.Oncogene2006;25:3818-22

[51] Foerster F,Müller L.NAFLD-driven HCC: safety and efficacy of current and emerging treatment options.J Hepatol2022;76:446-57

[52] Takahashi Y,Kusano H.Pathology and pathogenesis of metabolic dysfunction-associated steatotic liver disease-associated hepatic tumors.Biomedicines2023;11:2761 PMCID:PMC10604511

[53] Yu Q,Ma W.Postoperative prognosis of non-alcoholic fatty liver disease-associated intrahepatic cholangiocarcinoma: a multi-center propensity score matching analysis.J Gastrointest Surg2023;27:2403-13

[54] Le Roy B,Pittau G.Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma.Br J Surg2018;105:839-47

[55] Toyoda J,Takahashi T.Neoadjuvant therapy for extrahepatic biliary tract cancer: a propensity score-matched survival analysis.J Clin Med2023;12:2654 PMCID:PMC10095506

[56] Kato A,Ohtsuka M.Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study.Ann Surg Oncol2013;20:318-24

[57] Chang ME,Chen MH.Evaluation of prognostic factors and implication of lymph node dissection in intrahepatic cholangiocarcinoma: 10-year experience at a tertiary referral center.J Chin Med Assoc2017;80:140-6

[58] Weber SM,O'Reilly EM,Miyazaki M.Intrahepatic cholangiocarcinoma: expert consensus statement.HPB (Oxford)2015;17:669-80 PMCID:PMC4527852

[59] Benson AB,Abrams T.NCCN guidelines® insights: biliary tract cancers, version 2.2023.J Natl Compr Canc Netw2023;21:694-704

[60] Allen AM,Mara KC,Therneau TM.The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - a longitudinal cohort study.J Hepatol2019;71:1229-36 PMCID:PMC6921701

[61] Simon TG,Khalili H,Ludvigsson JF.Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.Gut2021;70:1375-82 PMCID:PMC8185553

[62] Zhou XD,Byrne CD.An international multidisciplinary consensus statement on MAFLD and the risk of CVD.Hepatol Int2023;17:773-91

[63] Cheng PN,Hou CJ.Taiwan association for the study of the liver-taiwan society of cardiology taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases.Clin Mol Hepatol2024;30:16-36 PMCID:PMC10776290

[64] Harrison SA,Neff GW.Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.Nat Med2023;29:2919-28 PMCID:PMC10667098

[65] Yang YY,Zhang NP,Liu TT.Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis.Acta Pharmacol Sin2022;43:1180-90 PMCID:PMC9061746

[66] Soto A,Martinino A.Exploring the multifaceted landscape of MASLD: a comprehensive synthesis of recent studies, from pathophysiology to organoids and beyond.Biomedicines2024;12:397 PMCID:PMC10886580

[67] El-Diwany R,Ejaz A.Intrahepatic cholangiocarcinoma.Surg Oncol Clin N Am2019;28:587-99

[68] Battistella S,Catanzaro E.Evolution of liver transplantation indications: expanding horizons.Medicina (Kaunas)2024;60:412 PMCID:PMC10972065

[69] Ioka T,Kobayashi S.Kansai Hepatobiliary Oncology Group (KHBO)Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA).J Hepatobiliary Pancreat Sci2023;30:102-10 PMCID:PMC10086809

[70] Kelley RK,Yoo C.KEYNOTE-966 InvestigatorsPembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2023;401:1853-65

[71] Tsung C,Ejaz A.Management of intrahepatic cholangiocarcinoma: a narrative review.Cancers (Basel)2024;16:739 PMCID:PMC10886475

[72] Bragazzi MC,Ribichini E,Cardinale V.Intrahepatic cholangiocarcinoma: evolving strategies in management and treatment.Dig Liver Dis2024;56:383-93

[73] Cotter TG.Nonalcoholic steatohepatitis after liver transplantation.Liver Transpl2020;26:141-59

[74] Hobeika C,Poté N.Short- and long-term outcomes of liver resection for intrahepatic cholangiocarcinoma associated with the metabolic syndrome.World J Surg2019;43:2048-60

[75] Meijer VE, Kalish BT, Puder M, Ijzermans JN. Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection.Br J Surg2010;97:1331-9

[76] Neal CP,Pointen E.Influence of hepatic parenchymal histology on outcome following right hepatic trisectionectomy.J Gastrointest Surg2012;16:2064-73

[77] Veteläinen R,van Gulik TM.Severe steatosis increases hepatocellular injury and impairs liver regeneration in a rat model of partial hepatectomy.Ann Surg2007;245:44-50 PMCID:PMC1867939

[78] McCuskey RS,Robertson GR,Perry M.Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice.Hepatology2004;40:386-93

[79] Poon RT.Assessment of hepatic reserve for indication of hepatic resection: how I do it.J Hepatobiliary Pancreat Surg2005;12:31-7

[80] Cauchy F,Dokmak S.Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome.Br J Surg2013;100:113-21

[81] Reddy SK,Varley PR.Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: a case-control study.Hepatology2012;56:2221-30

[82] Cauchy F,Belghiti J.Liver resection for HCC: patient's selection and controversial scenarios.Best Pract Res Clin Gastroenterol2014;28:881-96

[83] Rinella ME,Ratziu V.NAFLD Nomenclature consensus groupA multisociety Delphi consensus statement on new fatty liver disease nomenclature.Ann Hepatol2024;29:101133

[84] Ayada I,Alferink LJM,de Knegt RJ.Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: focusing on the non-overlap groups.Liver Int2022;42:277-87

[85] Alharthi J,Cua IH,Eslam M.Metabolic dysfunction-associated fatty liver disease: a year in review.Curr Opin Gastroenterol2022;38:251-60

[86] Younossi ZM,Stepanova M,Alqahtani S.Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.J Hepatol2024;80:694-701

[87] Suzuki K,Kurosaki M.Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease.Hepatol Res2024;54:600-5

[88] Zou H,Pan W.Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population.Front Nutr2024;11:1411802 PMCID:PMC11260733

[89] Guthold R,Riley LM.Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1·9 million participants.Lancet Glob Health2018;6:e1077-86

[90] Xie X,Xiao X.Healthy dietary patterns and metabolic dysfunction-associated fatty liver disease in less-developed ethnic minority regions: a large cross-sectional study.BMC Public Health2022;22:118 PMCID:PMC8764858

[91] Eslam M,Francque S.Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight.Nat Rev Gastroenterol Hepatol2022;19:638-51

[92] Chen F,Rogers GB.Lean NAFLD: a distinct entity shaped by differential metabolic adaptation.Hepatology2020;71:1213-27

[93] Younes R,Petta S.Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?.Gut2022;71:382-90

[94] Wei L,Luo Y.Lean non-alcoholic fatty liver disease and risk of incident diabetes in a euglycaemic population undergoing health check-ups: a cohort study.Diabetes Metab2021;47:101200

[95] Ye Q,Yeo YH.Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol2020;5:739-52

[96] Ito T,Zou B.The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040.Hepatol Int2021;15:366-79

[97] Reddy SK,Marsh JW.Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma.J Gastrointest Surg2013;17:748-55 PMCID:PMC4007003

[98] Eslam M,Mendez-Sanchez N.Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health.Lancet Gastroenterol Hepatol2020;5:713-5

[99] Alharthi J,Gloss BS.Loss of metabolic adaptation in lean MAFLD is driven by endotoxemia leading to epigenetic reprogramming.Metabolism2023;144:155583

[100] Sinn DH,Cho SJ.Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease.Eur J Gastroenterol Hepatol2021;33:e529-34

[101] Osadnik K,Lonnie M.Metabolically healthy obese and metabolic syndrome of the lean: the importance of diet quality. Analysis of MAGNETIC cohort.Nutr J2020;19:19 PMCID:PMC7041188